Correction--Santhera Successfully Places CHF 60 million

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
55
Correction--Santhera Successfully Places CHF 60 million Senior Convertible Bonds

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN

Liestal, Switzerland, February 10, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces the successful placement of CHF 60 million senior unsecured convertible bonds due 2022.

Santhera has successfully placed CHF 60 million senior unsecured convertible bonds (the "Convertible Bonds") due 2022. The Company intends to use the net proceeds from this placement primarily to fund the commercialization of Raxone ® in the currently approved indication, to prepare the market entry and commercial launch in subsequent indications, for investment into further clinical trials with Raxone and for other corporate purposes.

The Convertible Bonds have a 5-year maturity and a coupon of 5.00% per annum. The Conversion Price was fixed at CHF 86.4006, representing a premium of 20% over the volume weighted average price (VWAP) of the shares between the launch and pricing of the Convertible Bonds (the "Reference Share Price"). The Convertible Bonds are issued at 100% of their principal amount and, unless previously redeemed, converted or repurchased and cancelled, will mature on February 17, 2022, at 100% of their principal amount.

The Conversion Price will be reset after the first year if the VWAP of the shares during a specified period of time will be below the Reference Share Price. The new Conversion Price must not be lower than 75% of the Conversion Price at issuance. In addition, Santhera may call the Convertible Bonds at any time on or after the second anniversary of the issue date at par, plus accrued interest, if any, if the VWAP of the shares is at least 160% of the Conversion Price.

The Convertible Bonds will be convertible into 694,440 registered shares of Santhera Pharmaceuticals Holding AG, representing 11.1% of the current outstanding share capital of Santhera Pharmaceuticals Holding AG. The shares to be delivered upon conversion shall be sourced from conditional and, if needed, from authorized capital.

"The high demand from domestic and international investors is yet another sign of confidence in Santhera's potential and outlook. Proceeds from this latest financing enhance our financial flexibility in executing our development, regulatory and commercial activities as planned," said Christoph Rentsch , Chief Financial Officer of Santhera.

Application will be made for the Convertible Bonds to be admitted for listing and trading on the SIX Swiss Exchange, with provisional trading expected to start on or around February 16, 2017. Payment and settlement of the Convertible Bonds is expected to be on or around February 17, 2017.

Santhera agreed to a company lock-up ending 90 days after that date, subject to customary exceptions.

Bank am Bellevue and Kepler Cheuvreux acted as Joint Bookrunners on the Convertible Bond offering.

About Santhera Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera's lead product Raxone is authorized in the European Union, Norway, Iceland and Liechtenstein for the treatment of Leber's hereditary optic neuropathy (LHON). For Duchenne muscular dystrophy (DMD), the second indication for Raxone, Santhera has filed a Marketing Authorization Application (MAA) in the European Union and Switzerland. In collaboration with the US National Institute of Neurological Disorders and Stroke (NINDS) Santhera is developing Raxone in a third indication, primary progressive multiple sclerosis (PPMS), and omigapil for congenital muscular dystrophy (CMD), all areas of high unmet medical need. For further information, please visit the Company's website www.santhera.com .

Raxone ® is a trademark of Santhera Pharmaceuticals.

For further information, contact: Thomas Meier, PhD, Chief Executive Officer Phone +41 61 906 89 64 thomas.meier@santhera.com     Christoph Rentsch, Chief Financial Officer Phone +41 61 906 89 65 christoph.rentsch@santhera.com
US investor contact: Hans Vitzthum, LifeSci Advisors, LLC Phone +1 212 915 2568 hans@lifesciadvisors.com US Public Relations contact: Deanne Eagle, Planet Communications Phone +1 917 837 5866 deanne@planetcommunications.nyc

Disclaimer / Forward-looking statements This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This announcement may include projections and other "forward-looking" statements, expectations or estimates. Such statements reflect the current views of Santhera about future or uncertain events, achievements or performance. No assurances can be given that such events, achievements or performance will occur or have occurred as projected or estimated and actual events and results may differ materially from these statements. Readers should therefore not place reliance on these statements. The Company disclaims any obligation to update these statements.

Important Cautionary Statement This press release is not for release, publication or distribution in the United States of America, Canada, Japan or Australia, or in any other jurisdiction in which such distribution would be prohibited by applicable law.

This announcement is an advertisement and not a prospectus and not an offer of securities for sale in any jurisdiction, including in or into the United States of America, Australia, Canada or Japan or any jurisdiction in which offers or sales of the securities would be prohibited by applicable law. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. This announcement does not constitute an offer to sell, a solicitation of an offer to buy any of the bonds nor underlying shares described herein, or any kind of advice, nor shall there be any offer, solicitation or sale in any country or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any country or jurisdiction. This press release also does not constitute a prospectus as such term is understood pursuant to article 652a or article 1156 of the Swiss Federal Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange. The relevant information on the bonds and the issuer is only available in the preliminary and the final prospectus respectively the latter of which is currently expected to be published on or around February 13, 2017. The bonds are subject to the selling restrictions set out in the prospectus. The preliminary and the final prospectus will be available free of charge at Bank am Bellevue AG, Seestrasse 16, 8700 Küsnacht/Zurich, Switzerland (telephone number: +41 44 267 67 67; facsimile number: +41 44 267 67 50; email: prospectus@bellevue.ch), during regular business hours. This announcement and the information contained herein are not for distribution, directly or indirectly, in or into the United States of America and must not be distributed to U.S. persons (as defined in Regulation S of the U.S. Securities Act of 1933, as amended ("Securities Act")) or to publications with a general circulation in the United States. The securities referred to herein have not been and will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements. Within the United Kingdom, this announcement is directed only to persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("relevant persons"). The investment or investment activity to which this announcement relates is only available to and will only be engaged in with relevant persons and person who receive this announcement who are not relevant persons should not rely or act upon it.

# # #

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...7561df0753

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LONGi's Four Paths to Global Green Development

Updated Category News Views 62

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 149

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 469

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 283

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 92

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 34

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading

Top 5 Most Recently Viewed Articles

AAVantgarde's Professor Auricchio Receives Prestigious Role

Updated Category News Views 177

AAVantgarde's Professor Auricchio Achieves New Milestone MILAN, a milestone moment has arrived for AAVantgarde Bio as Professor Alberto Auricchio, the visionary Founder and Chief Scientific Officer, has been elected President of the European Society of Gene and Cell Therapy. This prestigious appointment recognizes his exceptional contributions and unwavering commitment to...

Continue Reading
How Bitcoin's Drop Affects Strategy Inc (NASDAQ: MSTR) Investors

Updated Category News Views 137

Understanding the Current Market Landscape As recent market trends demonstrate, Strategy Inc (NASDAQ: MSTR) is seeing significant activity. On one hand, the company is evidently reliant on the performance of Bitcoin. With such dependence, the fluctuations in the value of Bitcoin are crucial to the health of MSTR. This situation poses both risks and opportunities for...

Continue Reading
Significant Attorney Departures to Strengthen Association Law Firm

Updated Category News Views 99

Major Attorney Moves to Association Law Group (ALG) In a noteworthy shift within Florida's community association law landscape, several prominent attorneys have transitioned from Becker & Poliakoff to join the ranks of Association Law Group (ALG). Among them, Michael C. Gongora, Lilliana Farinas-Sabogal, and Adam Cervera are recognized for their extensive experience in...

Continue Reading
EQB's Commitment to Sustainability in Financial Services

Updated Category News Views 175

EQB Focuses on Sustainability in Its Latest Report EQB Inc. (TSX: EQB) has recently published a detailed Responsibility Report, highlighting significant strides towards its sustainability commitments. This annual report encapsulates the company's dedication to fostering an environment of innovation within the Canadian banking sector, with a particular focus on enriching...

Continue Reading
BofA's Downgrade of Sandvik: Navigating Market Pressures Ahead

Updated Category News Views 103

BofA Securities dropped a bomb on Sandvik AB back then by downgrading it from Neutral to Underperform. This move sent shockwaves through the trading floor, mainly because they saw some serious trouble brewing in Sandvik’s Machining and Manufacturing Solutions (SMMS) division. Traders were quick to pick up on the whispers about short cycle pressures that could really...

Continue Reading